Back to funds
View filing
Enavate Sciences GP, LLC
Updated 6 days agoManaged by Enavate Sciences Gp, Llc • Latest filing Q3 2026
Portfolio value
$279.8M
Q3 2026
Filings
4
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 4 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2025 | $506.8M |
| Q1 2026 | $351.5M |
| Q2 2026 | $345.4M |
| Q3 2026 | $279.8M |
Top holdings
8 positions as of Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | $78.7M | 2.92M | 28.14% | — | |
| 2 | $77.7M | 3.61M | 27.79% | — | |
| 3 | ? N/A BRAVEHEART BIO INC | $74.2M | 3.67M | 26.53% | — |
| 4 | $13M | 2.48M | 4.66% | — | |
| 5 | ? N/A UPSTREAM BIO INC | $13M | 2.46M | 4.63% | — |
| 6 | ? N/A BRIDGEBIO ONCOLOGY THERAPEUT | $10.8M | 2.63M | 3.85% | — |
| 7 | ? N/A COMPASS THERAPEUTICS INC | $8.1M | 7.79M | 2.90% | — |
| 8 | $4.2M | 1.04M | 1.50% | — |